Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599999 | 0.94 | MAPK14 (0.49) | MAPK14EGFRKDRSCN9APSEN1 | |
| SCHEMBL607542 | 0.92 | MAPK14 (0.47) | MAPK14EGFRKDRSCN9APSEN1 | |
| SCHEMBL599512 | 0.90 | MAPK14 (0.48) | MAPK14SCN9A | |
| SCHEMBL599750 | 0.90 | MAPK14 (0.46) | MAPK14KDRSCN9APSEN1PSEN2 | |
| SCHEMBL600374 | 0.89 | MAPK14 (0.47) | MAPK14SCN9APSEN1PSEN2APH1B | |
| SCHEMBL599346 | 0.87 | MAPK14 (0.52) | MAPK14SCN9A | |
| SCHEMBL599489 | 0.87 | MAPK14 (0.74) | MAPK14SCN9A | |
| SCHEMBL601105 | 0.85 | MAPK14 (0.51) | MAPK14SCN9APSEN1PSEN2APH1B | |
| SCHEMBL601357 | 0.84 | MAPK14 (0.46) | MAPK14SCN9A | |
| SCHEMBL599454 | 0.84 | MAPK14 (0.46) | MAPK14KDRSCN9APSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497269-B2 | Phthalazine compounds as p38 map kinase modulators and methods of use thereof | AMGEN INC. (US) | 2013-07-30 | — | — | US | claimed |
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2012-02-16 | — | — | US | claimed |
| WO-2010042649-A2 | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | claimed |
| US-8497269-B2 | Phthalazine compounds as p38 map kinase modulators and methods of use thereof | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010042649-A2 | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | MAPK1, MAPK4, MAPK12 | MAPK14 26/4885EGFR 3565/4885KDR 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.